Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS
Oslo, 9 April 2026: Lytix Biopharma AS (the “Company”) has granted 100,000 share options to primary insider Darlene Deptula-Hicks, a…
0,940€
3,75%
Echtzeit-Aktienkurs Lytix Biopharma AS
Bid:
Ask:
Nachrichten zur Lytix Biopharma AS Aktie
Lytix Biopharma AS - New share capital registered
Oslo, Norway, 24 February 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or…
Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report
Oslo, Norway, February 12, 2026 – Lytix Biopharma AS (“Lytix” or the “Company”) today published its interim financial report for…
Lytix Biopharma: Invitation to Q3 2025 Results Presentation
Oslo, Norway, November 14, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) will release its third quarter 2025 financial…
Lytix Biopharma AS reshuffled its Board after the Ordinary General Meeting
Oslo, Norway, April 29, 2025 – The Ordinary General Meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held…
Lytix Biopharma AS – Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference
Oslo, Norway, January 22, 2025 – Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, has presented clinical data on Lytix lead drug…
Lytix Biopharma AS - New share capital registered
Oslo, Norway, 15 January 2025: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or…
Lytix Biopharma AS - Cancellation of Subsequent Offering
Oslo, Norway, 7 January 2025: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or…
Lytix Biopharma AS - New share capital registered
Oslo, Norway, 23 December 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or…
Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG,…
Lytix Biopharma – Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG,…
Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG,…
Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization
Oslo, 19 November 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of…
Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization
Oslo, 29 August 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of…
Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14
Oslo, August 06, 2024. Lytix Biopharma announces that its licensing partner, Verrica Pharmaceuticals, will host an investor call to report…
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones
Oslo, 30 May 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of…
Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024
Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, will release its first quarter 2024 results on…
Lytix Biopharma – Minutes of Ordinary General Meeting
Oslo, Norway, May 14, 2024 – The Ordinary General Meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held…
Lytix Biopharma AS - New share capital registered
Oslo, Norway, 13 May 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or…
Correction in the notice of Annual General Meeting in Lytix Biopharma AS
Oslo, 3 May 2024: Reference is made to the stock exchange announcement published on 30 April 2024 where Lytix Biopharma…
Lytix Biopharma AS: Annual Report for 2023
Oslo, Norway, April 30, 2024 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces…
Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates
Oslo, Norway, 26 April 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or…
Lytix Biopharma AS – Share issue pursuant to board authorisation
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…
Lytix Biopharma AS – Minutes of extraordinary general meeting and final results of share offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…
Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity
Oslo, 25 April 2024. Lytix Biopharma announces that the Norwegian Medical Products Agency has approved the clinical trial application for…
Lytix Biopharma AS – Preliminary results in the share offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…